Promoting Recovery After STroke With Amantadine

Description

The investigators aim to examine whether amantadine can help patients recover from stroke. This will be a blinded randomized clinical trial (RCT). Patients will be randomized post-ischemic or hemorrhagic stroke either to the placebo arm or amantadine arm. Patients will be on study drug or placebo for 1 month but will be enrolled for 3 months total. At various time points patients will be examined and fill out questionnaires to determine level of stroke recovery.

Conditions

Stroke, Ischemic, Stroke Hemorrhagic

Talk to us

Study Overview

On this page

Study Details

Study overview

The investigators aim to examine whether amantadine can help patients recover from stroke. This will be a blinded randomized clinical trial (RCT). Patients will be randomized post-ischemic or hemorrhagic stroke either to the placebo arm or amantadine arm. Patients will be on study drug or placebo for 1 month but will be enrolled for 3 months total. At various time points patients will be examined and fill out questionnaires to determine level of stroke recovery.

Promoting Recovery After STroke With Amantadine

Promoting Recovery After STroke With Amantadine

Condition
Stroke, Ischemic
Intervention / Treatment

-

Contacts and Locations

Philadelphia

The Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States, 19104

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. 18 to 85 years old, male and female
  • 2. Modified Rankin Score (mRS)\<=2 prior to stroke
  • 3. Ischemic or hemorrhagic stroke as diagnosed by vascular neurologist or as proven on magnetic resonance imaging (MRI) or non-contrast head computed tomography NCHCT)
  • 4. 24 hours to 3 weeks after stroke onset or time last known well prior to detection of symptoms
  • 5. National Institute of Health Stroke Scale (NIHSS)\>=3 and NIHSS\<=15
  • 6. Creatinine Clearance of greater than or equal to 60 mL/min using the Cockroft- Gault equation.
  • 7. Have passed a swallow evaluation prior to drug administration
  • 8. The patient is an acute rehabilitation candidate or candidate for the Homeward Stroke Program
  • 9. Able to participate in administered tests
  • 1. Any degree of receptive aphasia
  • 2. Moderate or severe expressive aphasia
  • 3. Currently pregnant or plans to get pregnant
  • 4. Currently breastfeeding
  • 5. Any patient admitted with primary SubarachnoidH emorrhage (SAH )on either non-contrast head CT or MRI brain
  • 6. Diagnosis of dementia or mild cognitive impairment prior to index stroke
  • 7. Prior limb amputation
  • 8. Currently prescribed or taking a primary anticholinergic medication
  • 9. Currently enrolled in any other investigational pharmacologic or procedural clinical trial
  • 10. Malignancy with active treatment
  • 11. History of prior stroke with residual impairment
  • 12. Current or prior neuroleptic use
  • 13. History of suicidality or psychosis (The Columbia Suicide Severity Ratings Scale (C-SSRS) will be administered at the screening visit to assess depression and suicidal thoughts for subject eligibility. Any subjects who indicate severe depression or suicidal thoughts and/or attempts within the last year will not be eligible)
  • 14. Prior history of seizures
  • 15. Prior treatment with amantadine
  • 16. Parkinson's disease
  • 17. Amantadine allergy
  • 18. Elevated liver function tests (aspartate aminotransferase and alanine aminotransferase above the upper limit of normal) -

Ages Eligible for Study

18 Years to 85 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Pennsylvania,

Study Record Dates

2026-06-30